A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

(Reuters) -Regeneron shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of ...

Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition commonly ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug ...

An experimental COPD drug from Sanofi and Regeneron showed mixed results in a pair of studies, sending the companies' shares ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in one Phase 3 trial. A second test of the drug, itepekimab, was successful.

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...